Skip to main content
. 2013 Nov 5;8:4339–4350. doi: 10.2147/IJN.S51621

Figure 3.

Figure 3

In vivo anticancer activity of CT-NLC, T-NLC, and free tripterine. (A) Change in tumor volume over the course of treatment. (B) Calculated inhibition rate of tumor growth after 14 days of treatment.

Notes: Data represent the mean ± standard deviation (n=8). *P<0.05; **P<0.01 versus CT-NLC 4 mg/kg.

Abbreviations: T-NLC, tripterine-loaded nanostructured lipid carriers; CT-NLC, cell-penetrating peptide-coated T-NLC.